Bisphosphonate exposure and Atypical Femoral Fractures

Slides:

Advertisements

Similar presentations

Chapter 80 Chapter 80 Bisphosphonates: Pharmacology and Use in the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

Advertisements

Atypical Fractures of the Femur: Evaluation and Treatment by Travis Blood, R.J. Feller, Eric Cohen, Christopher T. Born, and Roman Hayda JBJS Reviews Volume.

ECTS symposium 5 Anabolic treatment of osteoporosis.

Chapter 54 Chapter 54 HIV and Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

Chapter 34: Biochemical Markers of Bone Turnover in Osteoporosis Pawel Szulc and Pierre D. Delmas.

Osteoporosis Update DR. SYLVIE OUELLETTE RHEUMATOLOGIST.

Therapeutic Implications

Chapter 62: Osteoporosis in Men

The relationship among history of falls, osteoporosis, and fractures in postmenopausal women Piet Geusens, MD, PhD, Philip Autier, MD, PhD, Steven Boonen,

Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis Peyman Hadji Critical Reviews in Oncology.

Chapter 38: Epidemiology of Osteoporotic Fractures

Chapter 61: Transplantation Osteoporosis

Effects of various bisphosphonates on clinical vertebral fractures (A), nonvertebral fractures (B), and hip fractures (C). PLB, placebo; RRR, relative.

THE EFFECTIVENESS OF ANNUAL ZOLEDRONIC ACID INFUSION VERSUS ORAL BISPHOSPHONATE: A MODELLING APPROACH Terence Ong1, 2, Matthey Jones3, Opinder Sahota1.

Chapter 55: Cost-Effectiveness of Osteoporosis Treatment

Efficacy and safety of hyaluronic acid in the management of osteoarthritis: Evidence from real-life setting trials and surveys Emmanuel Maheu, MD, François.

Placebo Metformin ***p < vs placebo

Incidence rates for the three common osteoporotic fractures

Ronald D. Emkey, MD, Mark Ettinger, MD

11/24/2018 OSTEOPOROSIS.

Evolution of extended-spectrum β-lactamases by mutation

Peripheral Arterial Disease: Diagnosis and Management

J Bone Miner Res 2015;30:1553 (Fig. 1)

RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer Matthew R. Smith European Urology Supplements

Skeletal Morbidity in Men with Prostate Cancer: Quality-of-Life Considerations throughout the Continuum of Care Fred Saad, Carl Olsson, Claude C. Schulman

Risk Factors for the Development of Bone Metastases in Prostate Cancer

Short-Bowel Syndrome Clinical Gastroenterology and Hepatology

Prevention of food allergy

Proceedings of the 2017 Santa Fe Bone Symposium: Insights and Emerging Concepts in the Management of Osteoporosis E. Michael Lewiecki, John P. Bilezikian,

Increased Exposure Improves Recruitment: Early Results of a Program Designed to Attract Medical Students Into Surgical Careers Kara A. Haggerty, BA,

Image with permission from PR Buenzli and NA Sims.

Lippuner et al Osteoporos Int 2011;22:2487

Yong-jiang Hei European Urology Supplements

Bone 2013; doi: /j.bone (Fig. 1)

Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis

Jacques Irani European Urology Supplements

Factors affecting radiation injury

The relationship among history of falls, osteoporosis, and fractures in postmenopausal women Piet Geusens, MD, PhD, Philip Autier, MD, PhD, Steven Boonen,

This Month in AJKD American Journal of Kidney Diseases

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

The Hallmarks of BPH Progression and Risk Factors

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma Fred Saad European Urology.

Osteoporos Int 2015;26:2243 (Fig. 2)

Bone 2013;56:23 (Fig. 1) Reproduced from Bone, 56:23-9, Copyright (2013), with permission from Elsevier.

M.Y. Chan, J.R. Center, J.A. Eisman, T.V. Nguyen

Alternate indications for varicocele repair: non-obstructive azoospermia, pain, androgen deficiency and progressive testicular dysfunction Peter N. Schlegel,

Bob Djavan European Urology Supplements

Cancer Treatment-Induced Bone Loss (CTIBL) in Prostate Cancer: Pathophysiology, Preclinical Findings, and Treatment with Zoledronic Acid Theresa A. Guise,

An informal discussion among emergency nurses about their current clinical practice: What’s new and what works Deborah Blazys, RN, BSN Journal of Emergency.

J Bone Miner Res 2013; doi: /jbmr.2072 (Fig. 1)

Bone 2014;61:191 (Fig. 2) Reproduced from Bone, 61: , Copyright (2014), with permission from Elsevier.

The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients Kurt Miller European Urology Supplements Volume.

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

JBMR 2012;doi:[ /jbmr.1760] (Fig. 3A)

Beyond Skeletal-Related Events

A Single Participant Exposed Twice to an Inflammatory Stimulus

Cardiovascular risk in chronic kidney disease

Change in cortical bone thickness among 64 women with osteopenia randomised to 14-month treatment with no mineral therapy (red bar), calcium gluconate.

New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer Noel W. Clarke European Urology Supplements

Glucocorticoid-induced osteoporosis: An update on effects and management Bjoern Buehring, MD, Ravi Viswanathan, MD, Neil Binkley, MD, William Busse, MD

Jan Roigas European Urology Supplements

Bone 2014;69C:89 (Fig. 2) Reproduced from Bone, 69C:89-97, Copyright (2014), with permission from Elsevier.

J Bone Miner Res 2014;doi: /jbmr.2325 (Fig. 2)

Lisa A. Beck, MD, Sarbjit Saini, MD

Volume 152, Issue 3, Pages (March 2019)

Michael Marberger European Urology Supplements

Pathophysiology of acute decompensated heart failure

Fig. 1: Relative risks of death from any cause among participants with various risk factors (e.g., history of hypertension, chronic obstructive pulmonary.

Current challenges in photoprotection

Presentation transcript:

Bisphosphonate exposure and Atypical Femoral Fractures JBMR 2012;27:2544 (Figs. 4, 2) Reproduced from J Bone Miner Res 2012;27:2544-50 with permission of the American Society of Bone and Mineral Research.

Cortical thickness and Atypical Fractures Osteoporos Int 2012;23:2893 (Fig. 1) Reproduced from Osteoporos Int 2012;23:2893-6 with permission from Springer.

N Engl J Med 2012;367:1714 (Fig. 2) From N Engl J Med, Steven Boonen, Jean-Yves Reginster, Jean-Marc Kaufman, et al., Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis, Volume 367, Page 1714. Copyright © (2012) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

*p<0.05 vs baseline p<0.001 vs placebo N Engl J Med 2012;367:1714 (Fig. 3) From N Engl J Med, Steven Boonen, Jean-Yves Reginster, Jean-Marc Kaufman, et al., Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis, Volume 367, Page 1714. Copyright © (2012) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

Bone 2012;50:1115 (Fig. 2) Reproduced from Bone, 50:1115-22, Copyright (2012), with permission from Elsevier.

Bone 2012;50:1115 (Figs. 4, 5) Reproduced from Bone, 50:1115-22, Copyright (2012), with permission from Elsevier.

1-year fracture incidence by age Types of fractures Osteoporos Int 2012;23:2863 (Figs. 1, 3) Reproduced from Osteoporos Int 2012;23:2863-71 with permission from Springer.